Lerivon

Mianserin hydrochloride, the active ingredient in Lerivon, is a tetracyclic antidepressant presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients. GNH USA supplies Lerivon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mianserin hydrochloride is employed primarily in the management of depressive disorders.

Major depressive disorder: reduction of depressive symptoms and improvement of overall mood.

Mianserin hydrochloride may cause a range of adverse reactions.

Common Side Effects: - Drowsiness or sedation - Dry mouth - Weight gain - Dizziness

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Cardiac arrhythmias such as QT prolongation - Severe hypotension - Hepatic dysfunction - Emergence of suicidal thoughts or behaviors

When prescribing or dispensing Lerivon, consider the following precautions.

Monitor blood pressure: watch for hypotension, especially during treatment initiation. Assess hepatic function: use caution in patients with liver impairment. Evaluate for suicidal ideation: observe mood changes throughout therapy. Avoid abrupt discontinuation: taper under medical supervision to reduce withdrawal risk. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Mianserin hydrochloride can interact with several medication classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - CNS depressants (e.g., benzodiazepines): enhanced sedation. - Serotonergic agents (e.g., SSRIs, SNRIs): potential serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive blood‑pressure lowering effect. - Anticholinergic drugs: increased anticholinergic burden. - Alcohol: may intensify sedative properties.